Related Experiment Video
Updated: Jan 15, 2026
09:19
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
9.6K
[Haemostasis. A search for an ideal antithrombotics agent]
1Unité d'hémostase, Département de médecine interne, Hôpitaux universitaires de Genève, 1211 Genève 14. philippe.deMoerloose@hcuge.ch
Revue Medicale Suisse
|March 19, 2005
Summary
New antithrombotic agents offer alternatives to traditional heparin and vitamin K antagonists, with improved efficacy and fewer side effects. Fondaparinux and ximelagatran show promise, though challenges like liver enzyme increases with ximelagatran remain.
Area of Science:
- Pharmacology
- Thrombosis Research
- Drug Development
Context:
- Established antithrombotic therapies, including heparins and vitamin K antagonists, are effective but associated with significant drawbacks such as injection requirements, need for regular laboratory monitoring, and potential side effects.
- The development of novel antithrombotic agents aims to overcome the limitations of current treatments, offering improved safety profiles and administration convenience.
Purpose:
- To review the current landscape of antithrombotic therapies, focusing on newly developed agents.
- To evaluate the efficacy, safety, and practical considerations of emerging antithrombotic drugs like fondaparinux and ximelagatran.
- To discuss the ongoing advancements and future directions in the field of antithrombotic drug discovery.
Summary:
- Heparins and vitamin K antagonists are mainstays in antithrombotic therapy but require injections or regular lab monitoring and carry side effect risks.
- Newer agents, fondaparinux and ximelagatran, are non-animal-derived, do not cause thrombocytopenia, and eliminate the need for lab controls.
- Fondaparinux demonstrates superior efficacy in orthopedic surgery compared to low molecular weight heparin, while oral ximelagatran faces challenges with elevated liver enzymes, limiting its widespread use.
Impact:
- Fondaparinux and ximelagatran represent significant advancements in antithrombotic treatment, offering enhanced patient convenience and potentially improved outcomes.
- The emergence of these novel agents, along with others in development, signifies a shift towards more targeted and safer antithrombotic strategies.
- Addressing the limitations of new drugs, such as ximelagatran's hepatotoxicity, is crucial for their successful integration into clinical practice and for guiding future drug design.
